← Back to patent-cliff list
HG-146
Tier C — Watch / tradeHG-146
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HDAC
Indications (approved)：Head and neck cancer, Adenoid cystic carcinoma, Lymphoma, Solid tumour, Multiple myeloma
Regional status
US
-
EU
-
China
Phase II
2024-12-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HG-146?
Approved indications include: Head and neck cancer, Adenoid cystic carcinoma, Lymphoma, Solid tumour, Multiple myeloma.
When does the HG-146 patent expire?
No public expiry year is available for HG-146 yet; this page updates once verified.
How do I get a quote for HG-146 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01